Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China

• Glavni autori: Kehui Meng (Autor), Heng Xiang (Autor), Meiyu Wu (Autor), Ouyang Xie (Autor), Andong Li (Autor), Chongqing Tan (Autor), Xiaomin Wan (Autor)
• Format: Knjiga
• Izdano: Frontiers Media S.A., 2024-11-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

AimsAssessing the cost-effectiveness of Nivolumab with Gemcitabine-Cisplatin for Advanced Urothelial Carcinoma (aUC) treatment from the perspective of Chinese payers.MethodsA Markov model assessed economic outcomes, estimating health outcomes in quality-adjusted life years (QALYs). One-way and proba...